Chemiesynth (Vapi) Limited announced its unaudited financial results for the third quarter of fiscal year 2025, ended December 31, 2025. The Gujarat-based chemical manufacturing company demonstrated revenue growth despite facing profitability challenges during the quarter.

Financial Performance Overview

The company's quarterly performance showed contrasting trends in revenue and profitability metrics:

Nine-Month Performance Analysis

The nine-month period ended December 31, 2025, reflected similar patterns with substantial revenue growth accompanied by increased losses:

Expense Structure and Cost Analysis

The company's expense breakdown for Q3FY25 revealed significant cost pressures across multiple categories. Other expenses constituted the largest component at ₹272.62 lakh, followed by cost of materials consumed at ₹117.36 lakh. Employee benefits expense stood at ₹87.11 lakh, while depreciation and amortization expense was ₹37.50 lakh. Finance costs decreased to ₹25.69 lakh from ₹34.40 lakh in Q3FY24.

Sequential Quarter Comparison

Comparing Q3FY25 with the previous quarter (Q2FY25), revenue declined from ₹687.15 lakh to ₹508.66 lakh, representing a 25.98% sequential decrease. The net loss also widened from ₹43.95 lakh in Q2FY25 to ₹69.71 lakh in Q3FY25.

Corporate Governance Updates

The Board of Directors meeting held on February 13, 2025, addressed several key matters:

• Approval of unaudited financial results for Q3FY25 and nine months ended December 31, 2025
• Consideration of the Limited Review Report from Statutory Auditor
• Reconstitution of the Nomination & Remuneration Committee

The meeting commenced at 2:00 p.m. and concluded at 3:00 p.m., with all proceedings conducted in accordance with regulatory requirements under SEBI Listing Regulations.

Company Profile and Operations

Chemiesynth (Vapi) Limited operates in the chemical manufacturing sector with its registered office located at Plot No. 27, GIDC, Phase-1, Vapi, Gujarat. The company maintains a single business segment focused on manufacturing of chemicals, with a paid-up equity capital of ₹307.00 lakh consisting of shares with a face value of ₹10 each.

Chemiesynth vapi Limited has announced the reconstitution of its Nomination and Remuneration Committee following a board meeting held on 13-02-2026. The changes were implemented with immediate effect to ensure compliance with regulatory requirements under the Companies Act, 2013 and SEBI listing regulations.

Committee Restructuring Details

The board approved significant changes to the committee composition to maintain compliance with Section 178 of the Companies Act, 2013 and Regulation 19 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Mr. Sandip Zaveri, who previously served as a Promoter Director on the committee, has ceased to be a member. In his place, Mr. Satish Zaveri, Promoter Non-Executive Director, has been appointed as a new member of the Nomination and Remuneration Committee.

Reconstituted Committee Composition

The newly reconstituted Nomination and Remuneration Committee comprises the following members:

The committee maintains a balanced composition with two independent directors and one non-executive non-independent director, ensuring proper governance structure as mandated by regulatory frameworks.

Regulatory Compliance

The company has confirmed that the reconstituted Nomination and Remuneration Committee is duly constituted in compliance with the provisions of the Companies Act, 2013 and SEBI (LODR) Regulations, 2015. This restructuring demonstrates the company's commitment to maintaining proper corporate governance standards and adhering to statutory requirements.

The announcement was made through a formal communication to BSE Limited, where the company's shares are listed under scrip code 539230. The notification was signed by Mr. Sandip Zaveri, Managing Director (DIN: 00158876), and digitally authenticated on 2026.02.13.